Difference between revisions of "Allopurinol (Zyloprim)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1966-08-19: Initial approval |
==Also known as== | ==Also known as== | ||
Revision as of 16:44, 9 May 2023
General information
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
History of changes in FDA indication
- 1966-08-19: Initial approval
Also known as
- Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway